Lucid Diagnostics Q2 revenue up 1000% YoY to $1.2mln, cash runway extended.

• Lucid Diagnostics processed 2,756 EsoGuard tests in Q2 2025. • Recognized $1.2 million in revenue. • Ended quarter with $30 million in proforma cash. • Extended runway past upcoming reimbursement milestones. • Will hold a conference call and webcast on August 13. • Multi-jurisdictional CAC meeting on Medicare Local Coverage Determination for EsoGuard to be held on September 4.

Lucid Diagnostics Inc. (Nasdaq: LUCD), a commercial-stage medical diagnostics company, has released its financial results for the second quarter (Q2) 2025, ending June 30, 2025. The company processed 2,756 EsoGuard® tests and recognized $1.2 million in revenue during the quarter, ending with over $30 million in proforma cash and extending its runway well past upcoming reimbursement milestones [1].

Lucid Diagnostics also reported a GAAP net loss of approximately $7.9 million or $(0.08) per common share for the quarter. However, the non-GAAP adjusted loss was approximately $9.9 million or $(0.10) per common share, reflecting the impact of stock-based compensation and other non-cash expenses [1].

The company's financial performance was bolstered by a strengthened balance sheet, with a public offering of common stock netting approximately $16.1 million in proceeds. This offering, combined with the existing cash on hand, extended the company's runway into 2026 [1].

Lucid Diagnostics has initiated patient testing and billing under its first positive commercial insurance coverage policy for EsoGuard from Highmark Blue Cross Blue Shield, which became effective May 26, 2025. Additionally, the company partnered with Hoag, a regional healthcare delivery network, to expand access to at-risk patients across its digestive health, primary care, and concierge medicine programs [1].

A significant milestone for the company is the upcoming MolDx Contractor Advisory Committee (CAC) meeting on September 4, 2025, to review the clinical evidence related to Local Coverage Determination (LCD) L39256 for EsoGuard. This meeting is part of the reconsideration process requested by Lucid in November 2024 [1].

The company will hold a conference call and webcast on Wednesday, August 13, 2025, at 8:30 AM EDT to discuss these financial results and business updates. Investors and stakeholders can access the webcast on the company's investor relations section at luciddx.com or by calling 1-800-836-8184 for U.S.-based callers and 1-646-357-8785 for international listeners [1].

References:
[1] https://www.prnewswire.com/news-releases/lucid-diagnostics-provides-business-update-and-reports-second-quarter-2025-financial-results-302528917.html